Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Biuletyn Polskiego Towarzystwa Onkologicznego Nowotwory
MENU
Na skróty Ahead of print Zgłaszanie manuskryptów Best Original Paper Award

dostęp otwarty

Tom 7, Nr 6 (2022)
Artykuł przeglądowy
Opublikowany online: 2022-10-12
Pokaż PDF (angielski) Pobierz plik PDF
Pobierz cytowanie

Treatment of metastatic uveal melanoma

Mateusz M. Polaczek1, Hanna Koseła-Paterczyk1
Biuletyn Polskiego Towarzystwa Onkologicznego Nowotwory 2022;7(6):434-439.
Afiliacje
  1. Department of Soft Tissue/Bone Sarcoma and Melanoma; Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland

dostęp otwarty

Tom 7, Nr 6 (2022)
Nowotwory rzadkie / Rare neoplasms
Opublikowany online: 2022-10-12

Streszczenie

Uveal melanoma is a rare malignancy with a poor prognosis. The risk of metastatic disease (mainly to the liver) exceeds 50% and is often observed many years after the primary treatment. The methods of local surgical treatment of meta­static lesions in the liver provide some chance for long-term survival but are possible in a small percentage of patients. The therapies currently used as a standard for cutaneous melanoma are not as effective in ocular melanoma. The first drug that prolongs the survival of patients is tebentafusp, but its applicability depends on the presence of HLA-A*02: 01 expression.

Streszczenie

Uveal melanoma is a rare malignancy with a poor prognosis. The risk of metastatic disease (mainly to the liver) exceeds 50% and is often observed many years after the primary treatment. The methods of local surgical treatment of meta­static lesions in the liver provide some chance for long-term survival but are possible in a small percentage of patients. The therapies currently used as a standard for cutaneous melanoma are not as effective in ocular melanoma. The first drug that prolongs the survival of patients is tebentafusp, but its applicability depends on the presence of HLA-A*02: 01 expression.

Pełny tekst:

Pokaż PDF (angielski) Pobierz plik PDF
Pobierz cytowanie

Słowa kluczowe

uveal melanoma; local treatment; immunotherapy

Informacje o artykule
Tytuł

Treatment of metastatic uveal melanoma

Czasopismo

Biuletyn Polskiego Towarzystwa Onkologicznego Nowotwory

Numer

Tom 7, Nr 6 (2022)

Typ artykułu

Artykuł przeglądowy

Strony

434-439

Opublikowany online

2022-10-12

Wyświetlenia strony

3195

Wyświetlenia/pobrania artykułu

112

Rekord bibliograficzny

Biuletyn Polskiego Towarzystwa Onkologicznego Nowotwory 2022;7(6):434-439.

Słowa kluczowe

uveal melanoma
local treatment
immunotherapy

Autorzy

Mateusz M. Polaczek
Hanna Koseła-Paterczyk

Referencje (79)
  1. Kaliki S, Shields CL. Uveal melanoma: relatively rare but deadly cancer. Eye (Lond). 2017; 31(2): 241–257.
    CrossRefPubMed
  2. Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology. 2011; 118(9): 1881–1885.
    CrossRefPubMed
  3. Kivelä T. The epidemiological challenge of the most frequent eye cancer: retinoblastoma, an issue of birth and death. Br J Ophthalmol. 2009; 93(9): 1129–1131.
    CrossRefPubMed
  4. Shields CL, Kaliki S, Cohen MN, et al. Prognosis of uveal melanoma based on race in 8100 patients: The 2015 Doyne Lecture. Eye (Lond). 2015; 29(8): 1027–1035.
    CrossRefPubMed
  5. Mahendraraj K, Shrestha S, Lau CS, et al. Ocular melanoma-when you have seen one, you have not seen them all: a clinical outcome study from the Surveillance, Epidemiology and End Results (SEER) database (1973-2012). Clin Ophthalmol. 2017; 11: 153–160.
    CrossRefPubMed
  6. Rodrigues M, Koning L, Coupland SE, et al. So Close, yet so Far: Discrepancies between Uveal and Other Melanomas. A Position Paper from UM Cure 2020. Cancers (Basel). 2019; 11(7): 1032.
    CrossRefPubMed
  7. Freton A, Chin KJ, Raut R, et al. Initial PET/CT staging for choroidal melanoma: AJCC correlation and second nonocular primaries in 333 patients. Eur J Ophthalmol. 2012; 22(2): 236–243.
    CrossRefPubMed
  8. Bagger M, Andersen MT, Andersen KK, et al. The prognostic effect of American Joint Committee on Cancer staging and genetic status in patients with choroidal and ciliary body melanoma. Invest Ophthalmol Vis Sci. 2014; 56(1): 438–444.
    CrossRefPubMed
  9. The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma I: characteristics of patients enrolled and not enrolled. COMS report no. 9. Am J Ophthalmol. 1998; 125(6): 767–778.
    CrossRefPubMed
  10. Shields CL, Furuta M, Thangappan A, et al. Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes. Arch Ophthalmol. 2009; 127(8): 989–998.
    CrossRefPubMed
  11. AJCC Ophthalmic Oncology Task Force. International Validation of the American Joint Committee on Cancer's 7th Edition Classification of Uveal Melanoma. JAMA Ophthalmol. 2015; 133(4): 376–383.
    CrossRefPubMed
  12. Kolandjian NA, Wei C, Patel SP, et al. Delayed systemic recurrence of uveal melanoma. Am J Clin Oncol. 2013; 36(5): 443–449.
    CrossRefPubMed
  13. Khoja L, Atenafu EG, Suciu S, et al. Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study. Ann Oncol. 2019; 30(8): 1370–1380.
    CrossRefPubMed
  14. NCCN Guidelines. Uveal Melanoma. Version 1.2022.
  15. The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma III: local complications and observations following enucleation COMS report no. 11. Am J Ophthalmol. 1998; 126(3): 362–372.
    CrossRefPubMed
  16. Jampol LM, Moy CS, Murray TG, et al. COMS Follow-up of Plaqued Eyes Working Group, Collaborative Ocular Melanoma Study Group (COMS Group). The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: IV. Local treatment failure and enucleation in the first 5 years after brachytherapy. COMS report no. 19. Ophthalmology. 2002; 109(12): 2197–2206.
    CrossRefPubMed
  17. Chang MY, McCannel TA. Local treatment failure after globe-conserving therapy for choroidal melanoma. Br J Ophthalmol. 2013; 97(7): 804–811.
    CrossRefPubMed
  18. Marinkovic M, Horeweg N, Fiocco M, et al. Ruthenium-106 brachytherapy for choroidal melanoma without transpupillary thermotherapy: Similar efficacy with improved visual outcome. Eur J Cancer. 2016; 68: 106–113.
    CrossRefPubMed
  19. Collaborative Ocular Melanoma Study Group. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15. Arch Ophthalmol. 2001; 119(5): 670–676.
    CrossRefPubMed
  20. Hemminki K, Zhang H, Czene K. Association of first ocular melanoma with subsequent cutaneous melanoma: results from the Swedish Family-Cancer Database. Int J Cancer. 2003; 104(2): 257–258.
    CrossRefPubMed
  21. Shields CL, Kaliki S, Furuta M, et al. American Joint Committee on Cancer Classification of Uveal Melanoma (Anatomic Stage) Predicts Prognosis in 7,731 Patients: The 2013 Zimmerman Lecture. Ophthalmology. 2015; 122(6): 1180–1186.
    CrossRefPubMed
  22. Diener-West M, Reynolds SM, Agugliaro DJ, et al. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. Arch Ophthalmol. 2005; 123(12): 1639–1643.
    CrossRefPubMed
  23. Kim IK, Lane AM, Gragoudas ES. Survival in patients with presymptomatic diagnosis of metastatic uveal melanoma. Arch Ophthalmol. 2010; 128(7): 871–875.
    CrossRefPubMed
  24. Onken MD, Worley LA, Char DH, et al. Collaborative Ocular Oncology Group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma. Ophthalmology. 2012; 119(8): 1596–1603.
    CrossRefPubMed
  25. Shields CL, Say EA, Hasanreisoglu M, et al. Personalized Prognosis of Uveal Melanoma Based on Cytogenetic Profile in 1059 Patients over an 8-Year Period: The 2017 Harry S. Gradle Lecture. Ophthalmology. 2017; 124(10): 1523–1531.
    CrossRefPubMed
  26. Cassoux N, Rodrigues MJ, Plancher C, et al. Genome-wide profiling is a clinically relevant and affordable prognostic test in posterior uveal melanoma. Br J Ophthalmol. 2014; 98(6): 769–774.
    CrossRefPubMed
  27. Vaquero-Garcia J, Lalonde E, Ewens KG, et al. PRiMeUM: A Model for Predicting Risk of Metastasis in Uveal Melanoma. Invest Ophthalmol Vis Sci. 2017; 58(10): 4096–4105.
    CrossRefPubMed
  28. Trolet J, Hupe P, Huon I, et al. Genomic profiling and identification of high-risk uveal melanoma by array CGH analysis of primary tumors and liver metastases. Invest Ophthalmol Vis Sci. 2009; 50(6): 2572–2580.
    CrossRefPubMed
  29. Ewens KG, Kanetsky PA, Richards-Yutz J, et al. Chromosome 3 status combined with BAP1 and EIF1AX mutation profiles are associated with metastasis in uveal melanoma. Invest Ophthalmol Vis Sci. 2014; 55(8): 5160–5167.
    CrossRefPubMed
  30. Lorenzo D, Ochoa M, Piulats JM, et al. Prognostic Factors and Decision Tree for Long-Term Survival in Metastatic Uveal Melanoma. Cancer Res Treat. 2018; 50(4): 1130–1139.
    CrossRefPubMed
  31. Rietschel P, Panageas KS, Hanlon C, et al. Variates of survival in metastatic uveal melanoma. J Clin Oncol. 2005; 23(31): 8076–8080.
    CrossRefPubMed
  32. Marshall E, Romaniuk C, Ghaneh P, et al. MRI in the detection of hepatic metastases from high-risk uveal melanoma: a prospective study in 188 patients. Br J Ophthalmol. 2013; 97(2): 159–163.
    CrossRefPubMed
  33. Piperno-Neumann S, Servois V, Mariani P, et al. Prospective study of surveillance testing for metastasis in 100 high-risk uveal melanoma patients. J Fr Ophtalmol. 2015; 38(6): 526–534.
    CrossRefPubMed
  34. Hendler K, Pe'er J, Kaiserman I, et al. Trends in liver function tests: a comparison with serum tumor markers in metastatic uveal melanoma (part 2). Anticancer Res. 2011; 31(1): 351–357.
    PubMed
  35. Mouriaux F, Diorio C, Bergeron D, et al. Liver function testing is not helpful for early diagnosis of metastatic uveal melanoma. Ophthalmology. 2012; 119: 1590–1595.
  36. Rantala ES, Hernberg M, Kivelä TT. Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis. Melanoma Res. 2019; 29(6): 561–568.
    CrossRefPubMed
  37. Kim JH, Shin SJ, Heo SJ, et al. Prognoses and Clinical Outcomes of Primary and Recurrent Uveal Melanoma. Cancer Res Treat. 2018; 50(4): 1238–1251.
    CrossRefPubMed
  38. Collaborative Ocular Melanoma Study Group. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15. Arch Ophthalmol. 2001; 119(5): 670–676.
    CrossRefPubMed
  39. Eskelin S, Pyrhönen S, Hahka-Kemppinen M, et al. A prognostic model and staging for metastatic uveal melanoma. Cancer. 2003; 97(2): 465–475.
    CrossRefPubMed
  40. Jochems A, van der Kooij MK, Fiocco M, et al. Metastatic Uveal Melanoma: Treatment Strategies and Survival-Results from the Dutch Melanoma Treatment Registry. Cancers (Basel). 2019; 11(7).
    CrossRefPubMed
  41. Agarwala SS, Eggermont AM. Metastatic melanoma to the liver: a contemporary and comprehensive review of surgical, systemic, and regional therapeutic options. Cancer. 2014; 120(6): 781–789.
    CrossRefPubMed
  42. European Medicines Agency. KIMMTRAK Summary of Product Characteristics (April 22, 2022).
  43. Sacco JJ, Carvajal R, Butler MO, et al. A phase (ph) II, multi-center study of the safety and efficacy of tebentafusp (tebe) (IMCgp100) in patients (pts) with metastatic uveal melanoma (mUM). SMO Immuno-Oncology Virtual Congress 2020 (9-12 December 2020).
  44. Nathan P, Hassel JC, Rutkowski P, et al. IMCgp100-202 Investigators. Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. N Engl J Med. 2021; 385(13): 1196–1206.
    CrossRefPubMed
  45. Kodjikian L, Grange JD, Baldo S, et al. Prognostic factors of liver metastases from uveal melanoma. Graefes Arch Clin Exp Ophthalmol. 2005; 243(10): 985–993.
    CrossRefPubMed
  46. Rivoire M, Kodjikian L, Baldo S, et al. Treatment of liver metastases from uveal melanoma. Ann Surg Oncol. 2005; 12: 422–428.
  47. Rowcroft A, Loveday BPT, Thomson BNJ, et al. Systematic review of liver directed therapy for uveal melanoma hepatic metastases. HPB (Oxford). 2020; 22(4): 497–505.
    CrossRefPubMed
  48. Eschelman DJ, Gonsalves CF, Sato T. Transhepatic therapies for metastatic uveal melanoma. Semin Intervent Radiol. 2013; 30(1): 39–48.
    CrossRefPubMed
  49. Gonsalves CF, Eschelman DJ, Sullivan KL, et al. Radioembolization as salvage therapy for hepatic metastasis of uveal melanoma: a single-institution experience. AJR Am J Roentgenol. 2011; 196(2): 468–473.
    CrossRefPubMed
  50. Ponti A, Denys A, Digklia A, et al. First-Line Selective Internal Radiation Therapy in Patients with Uveal Melanoma Metastatic to the Liver. J Nucl Med. 2020; 61(3): 350–356.
    CrossRefPubMed
  51. Gonsalves CF, Eschelman DJ, Adamo RD, et al. A Prospective Phase II Trial of Radioembolization for Treatment of Uveal Melanoma Hepatic Metastasis. Radiology. 2019; 293(1): 223–231.
    CrossRefPubMed
  52. Mariani P, Almubarak MM, Kollen M, et al. Radiofrequency ablation and surgical resection of liver metastases from uveal melanoma. Eur J Surg Oncol. 2016; 42(5): 706–712.
    CrossRefPubMed
  53. Bale R, Schullian P, Schmuth M, et al. Stereotactic Radiofrequency Ablation for Metastatic Melanoma to the Liver. Cardiovasc Intervent Radiol. 2016; 39(8): 1128–1135.
    CrossRefPubMed
  54. Schinzari G, Rossi E, Cassano A, et al. Cisplatin, dacarbazine and vinblastine as first line chemotherapy for liver metastatic uveal melanoma in the era of immunotherapy: a single institution phase II study. Melanoma Res. 2017; 27(6): 591–595.
    CrossRefPubMed
  55. Schmittel A, Schmidt-Hieber M, Martus P, et al. A randomized phase II trial of gemcitabine plus treosulfan versus treosulfan alone in patients with metastatic uveal melanoma. Ann Oncol. 2006; 17(12): 1826–1829.
    CrossRefPubMed
  56. Schmittel A, Schuster R, Bechrakis NE, et al. A two-cohort phase II clinical trial of gemcitabine plus treosulfan in patients with metastatic uveal melanoma. Melanoma Res. 2005; 15(5): 447–451.
    CrossRefPubMed
  57. Schmittel A, Scheulen ME, Bechrakis NE, et al. Phase II trial of cisplatin, gemcitabine and treosulfan in patients with metastatic uveal melanoma. Melanoma Res. 2005; 15(3): 205–207.
    CrossRefPubMed
  58. Schinzari G, Rossi E, Cassano A, et al. Cisplatin, dacarbazine and vinblastine as first line chemotherapy for liver metastatic uveal melanoma in the era of immunotherapy: a single institution phase II study. Melanoma Res. 2017; 27(6): 591–595.
    CrossRefPubMed
  59. Rantala ES, Hernberg M, Kivelä TT. Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis. Melanoma Res. 2019; 29(6): 561–568.
    CrossRefPubMed
  60. Buder K, Gesierich A, Gelbrich G, et al. Systemic treatment of metastatic uveal melanoma: review of literature and future perspectives. Cancer Med. 2013; 2(5): 674–686.
    CrossRefPubMed
  61. Leyvraz S, Piperno-Neumann S, Suciu S, et al. Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial. Ann Oncol. 2014; 25(3): 742–746.
    CrossRefPubMed
  62. de Lange MJ, Razzaq L, Versluis M, et al. Distribution of GNAQ and GNA11 Mutation Signatures in Uveal Melanoma Points to a Light Dependent Mutation Mechanism. PLoS One. 2015; 10(9): e0138002.
    CrossRefPubMed
  63. Van Raamsdonk CD, Bezrookove V, Green G, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature. 2009; 457(7229): 599–602.
    CrossRefPubMed
  64. Beadling C, Jacobson-Dunlop E, Hodi FS, et al. KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res. 2008; 14(21): 6821–6828.
    CrossRefPubMed
  65. Hofmann UB, Kauczok-Vetter CS, Houben R, et al. Overexpression of the KIT/SCF in uveal melanoma does not translate into clinical efficacy of imatinib mesylate. Clin Cancer Res. 2009; 15(1): 324–329.
    CrossRefPubMed
  66. Penel N, Delcambre C, Durando X, et al. O-Mel-Inib: a Cancéro-pôle Nord-Ouest multicenter phase II trial of high-dose imatinib mesylate in metastatic uveal melanoma. Invest New Drugs. 2008; 26(6): 561–565.
    CrossRefPubMed
  67. Nathan PD, Marshall E, Smith CT, et al. A Cancer Research UK two-stage multicenter phase II study of imatinib in the treatment of patients with c-kit positive metastatic uveal melanoma (ITEM). J Clin Oncol. 2012; 30: 8523–8523.
  68. Shoushtari AN, Kudchadkar RR, Panageas K, et al. A randomized phase 2 study of trametinib with or without GSK2141795 in patients with advanced uveal melanoma. J Clin Oncol. 2016; 34: 9511–9511.
  69. Carvajal RD, Sosman JA, Quevedo JF, et al. Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. JAMA. 2014; 311(23): 2397–2405.
    CrossRefPubMed
  70. Carvajal RD, Piperno-Neumann S, Kapiteijn E, et al. Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT). J Clin Oncol. 2018; 36(12): 1232–1239.
    CrossRefPubMed
  71. Bhatia S, Moon J, Margolin KA, et al. Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512. PLoS One. 2012; 7(11): e48787.
    CrossRefPubMed
  72. Piperno-Neumann S, Diallo A, Etienne-Grimaldi MC, et al. Phase II Trial of Bevacizumab in Combination With Temozolomide as First-Line Treatment in Patients With Metastatic Uveal Melanoma. Oncologist. 2016; 21(3): 281–282.
    CrossRefPubMed
  73. Zimmer L, Vaubel J, Mohr P, et al. Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma. PLoS One. 2015; 10(3): e0118564.
    CrossRefPubMed
  74. Joshua AM, Monzon JG, Mihalcioiu C, et al. A phase 2 study of tremelimumab in patients with advanced uveal melanoma. Melanoma Res. 2015; 25(4): 342–347.
    CrossRefPubMed
  75. Johnson DB, Bao R, Ancell KK, et al. Response to Anti-PD-1 in Uveal Melanoma Without High-Volume Liver Metastasis. J Natl Compr Canc Netw. 2019; 17(2): 114–117.
    CrossRefPubMed
  76. van der Kooij MK, Joosse A, Speetjens FM, et al. Anti-PD1 treatment in metastatic uveal melanoma in the Netherlands. Acta Oncol. 2017; 56(1): 101–103.
    CrossRefPubMed
  77. Schadendorf D, Ascierto PA, Haanen JB, et al. Efficacy and safety of nivolumab (NIVO) in patients with advanced melanoma (MEL) and poor prognostic factors who progressed on or after ipilimumab (IPI): Results from a phase II study (CheckMate 172). J Clin Oncol. 2017; 35: 9524–9524.
  78. Piulats JM, Espinosa E, de la Cruz Merino L, et al. Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402). J Clin Oncol. 2021; 39(6): 586–598.
    CrossRefPubMed
  79. Pelster MS, Gruschkus SK, Bassett R, et al. Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study. J Clin Oncol. 2021; 39(6): 599–607.
    CrossRefPubMed

Regulamin

Ważne: serwis https://journals.viamedica.pl/ wykorzystuje pliki cookies. Więcej >>

Używamy informacji zapisanych za pomocą plików cookies m.in. w celach statystycznych, dostosowania serwisu do potrzeb użytkownika (np. język interfejsu) i do obsługi logowania użytkowników. W ustawieniach przeglądarki internetowej można zmienić opcje dotyczące cookies. Korzystanie z serwisu bez zmiany ustawień dotyczących cookies oznacza, że będą one zapisane w pamięci komputera. Więcej informacji można znaleźć w naszej Polityce prywatności.

Czym są i do czego służą pliki cookie możesz dowiedzieć się na stronie wszystkoociasteczkach.pl.

Wydawcą serwisu jest VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, e-mail: viamedica@viamedica.pl